Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of antibodies at 40 months and PCV13 booster immunogenicity after infant PCV7 or PCV13 vaccination
2009-017498-39Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Mar 2010
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Prevnar 13 and pneumococcal 7-valent conjugate vaccine in pneumococcal disease, invasive pneumococcal disease (IPD), Pneumococcal pneumonia (PP) and 1 more (2 arms), sponsored by University of Oxford. Primary endpoint: Antibody persistence in prior PCV13 recipients. Started Mar 2010; status: completed.
02
Drugs
Prevnar 13pneumococcal 7-valent conjugate vaccine
03
Conditions
pneumococcal diseaseinvasive pneumococcal disease (IPD)Pneumococcal pneumonia (PP)acute otitis media (AOM)
Beyond the preview
Go deeper on 2009-017498-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017498-39.